Juan Carlos Fernández de Córdova-Aguirre

Juan Carlos Fernández de Córdova-Aguirre

Auto-generated profile, based on publicly available information

Juan Carlos Fernández de Córdova-Aguirre

Hospital del Río, Cuenca, Ecuador

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2019 in Revista Alergia México
Verified
Journal Article
Open access
PDF file
CSCentro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
Centro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
JLJorge A. Luna-Pech
Jorge A. Luna-Pech
NRNoel Rodríguez-Pérez
Noel Rodríguez-Pérez
MRMónica Rodríguez-González
Mónica Rodríguez-González
AAAlfredo Arias-Cruz
Alfredo Arias-Cruz
MMMiguel Alejandro Medina-Ávalos
Miguel Alejandro Medina-Ávalos
Background: In Mexico, allergen immunotherapy (AIT) and immunotherapy with hymenoptera venom (VIT) is traditionally practiced combining aspects of the European and American school. In addition, both types of extracts (European and American) are commercially available in Mexico. Moreover, for an adequate AIT/VIT a timely diagnosis is crucial. Therefore, there is a need for a widely accepted, up-to-date national immunotherapy guideline that covers diagnostic issues, indications, dosage, mechanisms, adverse effects and future expectations of AIT (GUIMIT 2019).Method: With nationwide groups of allergists participating, including delegates from postgraduate training-programs in Allergy/Immunology-forming, the guideline document was developed according to the ADAPTE methodology: the immunotherapy guidelines from European Academy of Allergy and Clinical Immunology, German Society for Allergology and Clinical Immunology, The American Academy of Allergy, Asthma and Immunology and American College of Allergy, Asthma, and Immunology were selected as mother guidelines, as they received the highest AGREE-II score among international guidelines available; their evidence conforms the scientific basis for this document.Results: GUIMIT emanates strong or weak (suggestions) recommendations about practical issues directly related to in vivo or in vitro diagnosis of IgE mediated allergic diseases and the preparation and application of AIT/VIT and its adverse effects. GUIMIT finishes with a perspective on AIT modalities for the future. All the statements were discussed and voted on until > 80 % consensus was reached.Conclusion: A wide and diverse group of AIT/VIT experts issued transculturized, evidence-based recommendations and reached consensus that might improve and standardize AIT practice in Mexico.

1 August 2020 in World Allergy Organization Journal
Verified
Journal Article
Open access
CSCentro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
Centro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
NRNoel Rodríguez-Pérez
Noel Rodríguez-Pérez
JLJorge A. Luna-Pech
Jorge A. Luna-Pech
MRMónica Rodríguez-González
Mónica Rodríguez-González
MBMaría Virginia Blandón-Vijil
María Virginia Blandón-Vijil
MMMiguel Alejandro Medina-Ávalos
Miguel Alejandro Medina-Ávalos
Allergen immunotherapy (AIT) has a longstanding history and still remains the only disease-changing treatment for allergic rhinitis and asthma. Over the years 2 different schools have developed their strategies: the United States (US) and the European. Allergen extracts available in these regions are adapted to local practice. In other parts of the world, extracts from both regions and local ones are commercialized, as in Mexico. Here, local experts developed a national AIT guideline (GUIMIT 2019) searching for compromises between both schools. Using ADAPTE methodology for transculturizing guidelines and AGREE-II for evaluating guideline quality, GUIMIT selected 3 high-quality Main Reference Guidelines (MRGs): the European Academy of Allergy, Asthma and Immunology (EAACI) guideines, the S2k guideline of various German-speaking medical societies (2014), and the US Practice Parameters on Allergen Immunotherapy 2011. We formulated clinical questions and based responses on the fused evidence available in the MRGs, combined with local possibilities, patient's preference, and costs. We came across several issues on which the MRGs disagreed. These are presented here along with arguments of GUIMIT members to resolve them. GUIMIT (for a complete English version, Supplementary data) concluded the following: Related to the diagnosis of IgE-mediated respiratory allergy, apart from skin prick testing complementary tests (challenges, in vitro testing and molecular such as species-specific allergens) might be useful in selected cases to inform AIT composition. AIT is indicated in allergic rhinitis and suggested in allergic asthma (once controlled) and IgE-mediated atopic dermatitis. Concerning the correct subcutaneous AIT dose for compounding vials according to the US school: dosing tables and formula are given; up to 4 non-related allergens can be mixed, refraining from mixing high with low protease extracts. When using European extracts: the manufacturer's indications should be followed; in multi-allergic patients 2 simultaneous injections can be given (100% consensus); mixing is discouraged. In Mexico only allergoid tablets are available; based on doses used in all sublingual immunotherapy (SLIT) publications referenced in MRGs, GUIMIT suggests a probable effective dose related to subcutaneous immunotherapy (SCIT) might be: 50–200% of the monthly SCIT dose given daily, maximum mixing 4 allergens. Also, a table with practical suggestions on non-evidence-existing issues, developed with a simplified Delphi method, is added. Finally, dissemination and implementation of guidelines is briefly discussed, explaining how we used online tools for this in Mexico. Countries where European and American AIT extracts are available should adjust AIT according to which school is followed.

3 May 2023 in World Allergy Organization Journal
Verified
Journal Article
Open access
CSCentro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
Centro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
BMBlanca María Morfin-Maciel
Blanca María Morfin-Maciel
MBMartin Bedolla-Barajas
Martin Bedolla-Barajas
ALAna López-Bago
Ana López-Bago
ENElsy Maureen Navarrete-Rodríguez
Elsy Maureen Navarrete-Rodríguez
LMLeonor Villa Médica
Leonor Villa Médica
Allergen immunotherapy (AIT) brings along changes in the immune system, restoring dendritic cell function, reducing T2 inflammation and augmenting the regulatory cell activation. Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, interferes with the immune system causing immune suppression during the first phase and over-activation in more advanced disease. We decided to explore the interaction of both in a real-world observational trial. We registered COVID-19 outcomes in patients with allergic disorders in Latin America, treated with and without AIT. The registry was conducted during the first 1.3 years of the pandemic, with most of the data collected before COVID-19 vaccination was concluded in most countries. Data collection was anonymous via a web-based instrument. Ten countries participated. 630/1095 (57.6%) of the included patients received AIT. Compared to patients without AIT, those treated with AIT had a reduced risk ratio (RR) for COVID-19 lower respiratory symptoms (RR 0.78, 95% CI: 0.6703–0.9024; p = 0.001662) and need for oxygen therapy (RR 0.65, 95% CI: 0.4217–0.9992; p = 0.048). In adherent patients on maintenance sublingual immunotherapy/subcutaneous immunotherapy (SLIT/SCIT) the RR reduction was larger [RR = 0.6136 (95% CI 0.4623–0.8143; p < 0.001) and RR: 0.3495 (95% CI 0.1822–0.6701; p < 0.005), respectively]. SLIT was slightly more effective (NS). We excluded age, comorbidities, level of health care attendance, and type of allergic disorder as confounders, although asthma was related to a higher frequency of severe disease. When analyzing patients with allergic asthma (n = 503) the RR reduction favoring AIT was more pronounced with 30% for lower respiratory symptoms or worse (RR 0.6914, 95% CI 0.5264 to 0.9081, p = 0.0087) and 51% for need of oxygen therapy or worse (RR 0.4868, 95% CI 0.2829–0.8376, p = 0.0082). Among severe allergic patients treated with biologics (n = 24) only 2/24 needed oxygen therapy. There were no critical cases among them. In our registry AIT was associated with reduced COVID-19 severity.

31 March 2014 in Revista Alergia México
Verified
Journal Article
Open access
PDF file
JCJuan Carlos Fernández de Córdova-Aguirre
Juan Carlos Fernández de Córdova-Aguirre
AVAndrea Aida Velasco-Medina
Andrea Aida Velasco-Medina
DCDiego Antonio Cariño-Cartagena
Diego Antonio Cariño-Cartagena
GVGuillermo Velázquez-Sámano
Guillermo Velázquez-Sámano
Allergic bronchopulmonary aspergillosis is a slowly progressive disease, caused by the fungus Aspergillus fumigatus hypersensitivity when it is found in the airway. It usually affects asthmatics and patients with cystic brosis. We report the case of a 20-year-old male patient, student, farmer and rancher with chronic respiratory disease. The diagnosis of allergic bronchopulmonary aspergillosis was made on the basis of the clinical symptoms and complementary studies.

4 April 2019 in Revista Alergia México
Verified
Journal Article
Open access
PDF file
JCJuan Carlos Fernández de Córdova-Aguirre
Juan Carlos Fernández de Córdova-Aguirre
AVAndrea Aida Velasco-Medina
Andrea Aida Velasco-Medina
CUCésar Urquiza
César Urquiza
KGKarol Andrea Guzmán-Guillén
Karol Andrea Guzmán-Guillén
GVGuillermo Velázquez-Sámano
Guillermo Velázquez-Sámano
Background: Many studies in children had identified risk factors associated with partly or uncontrolled asthma. In adults, factors related to asthma control were not well defined.Objective: To find the factors related to partly or uncontrolled asthma in adults.Methods: Asthmatic adults who had severity at least in the mild persistent level, were recruited. The asthma control levels were classified as controlled, partly controlled and uncontrolled according to the Global Initiative for Asthma guideline. Risk factors were compared between the patients with controlled and partly controlled/ uncontrolled asthma groups.Results: two hundred (75.5 % females) were included. The mean age was 38.4 ± 11.93 years old. There were 100 patients (50 %) in the controlled and 100 patients (50 %) in partly controlled and uncontrolled asthma group. For asthma severity, 35 patients (88.2 %) were in mild persistent, 14 patients (10 %) in moderate persistent and 97 patients (1.8 %) in severe persistent groups. The absence of stress yielded an OR = 0.41 (95 % CI = 0.23-0.75), p = 0.03. While active smoking, OR = 4.23 (95 % CI = 1.35-13.2), p = 0.007. Patients who have no contact with stuffed animals or rugs have OR = 0.4 (IC 95 % = 0.2-0.79). It was important the result of the patients that if they correctly use their inhalers OR = 0.36 (IC 95 % = 0.13-0.97), p = 0.031.Conclusions: Current and active smoking and atopic dermatitis are risk factors. As a protective factor to the normal levels of eosinophils in blood, correct use of inhalers, FEV1 > 80 %, the absence of stress and the absence of contact with carpets and stuffed animals.

12 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
GFGuillermo Guidos Fogelbach
Guillermo Guidos Fogelbach
AVAndrea Aida Velasco-Medina
Andrea Aida Velasco-Medina
FRFreya Helena Campos Romero
Freya Helena Campos Romero
NANora Alarcón
Nora Alarcón
AGAntonio Albarrán Godínez
Antonio Albarrán Godínez
RZRicardo Zwiener
Ricardo Zwiener
Background: Current international hereditary angioedema (HAE) guidelines and treat-to-target recommendations consistently emphasize accurate diagnosis, early on-demand treatment of attacks, appropriate short-term prophylaxis for procedures, individualized long-term prophylaxis (LTP), and routine assessment of disease control and quality of life. Published information on how these recommendations are implemented in Latin America remains limited. We therefore aimed to assess the extent to which a Latin American expert panel converges with recommendations across current international HAE guidelines and consensus documents and to identify the principal barriers affecting real-world implementation in the region. Methods: A scientific committee developed and externally validated a 74-item questionnaire (domains summarized in Supplementary Table S1) and conducted a 2-round Delphi process among Latin American HAE experts. Consensus items were rated on a 9-point agreement scale, with consensus defined a priori as at least two-thirds of panelists scoring within a 3-point band in the agreement (7-9) or disagreement (1-3) range. Descriptive items captured expert-reported diagnostic testing, acute and preventive treatment patterns, monitoring practices, and implementation determinants using 5-point Likert scales. Instrument validation (July-November 2024) demonstrated high inter-rater agreement (Kendall W = 0.84; p < 0.001) and excellent internal consistency (Cronbach alpha = 0.92). Results: Thirty experts from 10 countries completed the process (Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Panama, Peru, Uruguay, Venezuela). Panel consensus broadly converged with recommendations across current international HAE guidelines and consensus documents on core diagnostic work-up (C4 plus C1-INH antigen and function; 84% consensus), selective use of genetics (97% consensus), first-line targeted LTP (pdC1-INH, Lanadelumab, Berotralstat; 94% consensus), retention of on-demand therapy for breakthrough attacks and for patients without access to LTP, routine monitoring, and management in special populations. The principal novel finding was an implementation feasibility gap: frequent or constant interruptions in prophylaxis supply were reported by 19/30 experts (63%), including 13/23 (57%) practicing in settings where public or insurance coverage was reported. Across the panel, cost (19/30; 63%) and medicine availability (8/30; 27%) were the most commonly cited barriers, with additional constraints related to diagnostic testing access and administrative pathways. Conclusions: Latin American expert consensus largely converges with recommendations across current international HAE guidelines and consensus documents on diagnosis, acute management, prophylaxis selection, monitoring, and special-population care. The dominant divergence is not clinical disagreement but implementation feasibility—particularly access to diagnostic testing, financing mechanisms, medicine availability, and continuity of supply. These findings provide region-specific evidence to contextualize international recommendations and support implementation strategies tailored to Latin America.